RxDoctor Payments Data

Matthew Nguyen, MD

Family Medicine · Prosper, TXNPI 1710540174

Payments from drug & device makers

$5,312in general payments, 2019–2025

Across 213 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$649
  • GSK$356
  • Abbott$333
  • AbbVie$322
  • Novo Nordisk$317
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,312 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$15,664
Medicare patients
78
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$27,759
OzempicSemaglutide12$17,984
EliquisApixaban12$11,002
JardianceEmpagliflozin12$7,379
Atorvastatin Calcium120$1,023
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$961
Losartan Potassium95$892
Duloxetine Hcl27$810
Omeprazole34$740
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide31$728
Amlodipine Besylate96$687
Fluticasone Propionate42$610
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$576
Ezetimibe20$574
Levothyroxine Sodium67$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$649$27,75925 claims
Novo NordiskOzempic$317$17,98412 claims
PfizerEliquis$218$11,00212 claims
Boehringer IngelheimJardiance$216$7,37912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Prosper

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →